The Effects of Anlotinib Combined with Chemotherapy following Progression on Cyclin‐Dependent Kinase 4/6 Inhibitor in Hormone Receptor‐Positive Metastatic Breast Cancer
The Breast Journal · 2024
DOI: 10.1155/2024/5396107 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Breast Journal, 2024. Verfasst von Ting Xu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Quinolines, Indoles, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Xisike Clinical Oncology Research Foundation.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
Endocrine therapy combined with cyclin‐dependent kinase (CDK) 4/6 inhibitors (CDK4/6i) is the preferred treatment for hormone receptor‐positive (HR+)/human epidermal growth factor receptor 2‐negative (HER2–) metastatic breast cancer (MBC). However, there are currently no recommendations for therapeutic strategies after progression on CDK4/6i‐based treatment. This study aimed to examine the efficacy and safety of anlotinib plus chemotherapy in HR+/HER2– MBC after progression on CDK4/6 inhibitors.
Methods
We collected data from 32 patients with HR+/HER2– MBC treated with anlotinib plus chemotherapy after progressing on CDK4/6i at Jiangsu Cancer Hospital from March 2020 to October 2023. The median follow‐up was 9.1 months (range, 2.0–19.7 months) as of the data cutoff date in October 2023. The primary endpoint was median progression‐free survival (PFS); secondary endpoints included objective response rate (ORR), disease control rate (DCR), and adverse events.
Results
The median PFS (mPFS) of all patients was 7.6 months (95% confidence interval (CI), 5.75–9.45). There was no significant difference in mPFS between patients who responded to prior CDK4/6i treatment and those who did not (8.3 months vs. 6.8 months, p = 0.580). Besides, the ORR was 34.4% and DCR was 93.8%. The most frequently observed adverse events were anemia (50.0%), neutropenia (40.6%), thrombocytopenia (34.4%), and epistaxis (34.4%). Dose interruption or reductions due to adverse events occurred in 2 (6.3%) and 5 (15.6%) patients, respectively.
Conclusions
The study preliminarily demonstrates that anlotinib combined with chemotherapy may be an optional recommendation for patients with HR+/HER2– metastatic breast cancer who have progressed after CDK4/6i.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oncology The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
- Department of Chemotherapy Jiangsu Cancer Hospital Jiangsu Institute of Cancer Research The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
ORCID-Profile: Ting Xu, Weili Xiong, Lili Zhang, Yuan Yuan
Förderung
- Beijing Xisike Clinical Oncology Research Foundation
Zitieren
APA
Xu, T., Xiong, W., Zhang, L., & Yuan, Y. (2024). The Effects of Anlotinib Combined with Chemotherapy following Progression on Cyclin‐Dependent Kinase 4/6 Inhibitor in Hormone Receptor‐Positive Metastatic Breast Cancer. The Breast Journal. https://doi.org/10.1155/2024/5396107
Vancouver
Xu T, Xiong W, Zhang L, Yuan Y. The Effects of Anlotinib Combined with Chemotherapy following Progression on Cyclin‐Dependent Kinase 4/6 Inhibitor in Hormone Receptor‐Positive Metastatic Breast Cancer. The Breast Journal. 2024. doi:10.1155/2024/5396107
BibTeX
@article{Xu2024,
author = {Xu, Ting and Xiong, Weili and Zhang, Lili and Yuan, Yuan},
title = {The Effects of Anlotinib Combined with Chemotherapy following Progression on Cyclin‐Dependent Kinase 4/6 Inhibitor in Hormone Receptor‐Positive Metastatic Breast Cancer},
journal = {The Breast Journal},
year = {2024},
doi = {10.1155/2024/5396107}
}
EUVIMED